Denmark
Fida Biosystems is a biotechnology startup based in Denmark, focused on in solution characterisation and quantification of proteins and nanoparticles. The company was founded in 2013 and specializes in a new proprietary technology that enables the quantification and characterization of a wide range of particles, including antibodies, liposomes, and membrane embedded proteins. This technology is characterized by its speed, requiring only minutes to provide precise information about various properties such as concentration, size, conformational changes, and multiple bindings.
One of the key advantages of Fida Biosystems' technology is its ability to operate in native environments, providing in-built assay quality control and automation. The technology is also exceptionally tolerant to various sample matrices, including plasma, serum, and cell lysate. By focusing on binding in homogeneous solutions, it avoids complications related to non-specific surface adsorption and challenging assay development.
Despite the impressive potential of its technology, Fida Biosystems does not have publicly disclosed information regarding its last investment or investors. However, the company's innovative approach and its ability to address significant challenges in protein and nanoparticle characterization position it as a potentially promising opportunity for venture capital investment within the biotechnology and life sciences industries.
